Kevin Hern | VP, IR |
Dave Ricks | Chairman and CEO |
Josh Smiley | CFO |
Dan Skovronsky | President, Lilly Research Laboratories |
Christi Shaw | President of Lilly Bio-Medicines |
Anne White | President of Lilly Oncology |
Enrique Conterno | President, Lilly Diabetes and Lilly USA |
Kim Macko | IR |
Mike Czapar | IR |
Seamus Fernandez | Guggenheim Securities |
Steve Scala | Cowen & Company |
Chris Schott | JPMorgan |
Louise Chen | Cantor Fitzgerald |
Alex Arfaei | BMO Capital Markets |
Geoff Meacham | Barclays Capital |
David Risinger | Morgan Stanley |
Vamil Divan | Credit Suisse |
Vineeth Agrawal | Citi |
Umer Raffat | Evercore ISI |
Ladies and gentlemen, thank you for standing by, and welcome to the Eli Lilly Fourth Quarter 2018 Earnings Call. At this time, all the participant lines are in a listen-only mode. There will be an opportunity for your questions, and instructions will be given at that time. [Operator Instructions] As a reminder, today's call is being recorded. I'll turn the conference now to Mr.